Investors / filer profile

Cohlhepp Ryan

President, COO & Interim CEO

active in 1 company

Pro
Bought: Pro
Sold: 34
Filings: 1
Companies: 2026-09-08
Last filed

EDGAR · CIK 0002034665 ↗

Track record

How each disclosed position did against the S&P ~6 months later

No positions we can measure against the market yet — outcomes appear once a disclosed buy is ~6 months old.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$0.0000 bought · −$3.75M sold

All filings on record

Every Form 4 transaction we track for this filer


BCAXBicara Therapeutics Inc.	Sell $80.7K · 3,442 sh	2026-09-08	—
BCAXBicara Therapeutics Inc.	Sell $320.1K · 14,058 sh	2026-09-08	—
BCAXBicara Therapeutics Inc.	Exercise $66.3K · 17,500 sh	2026-09-08	—
BCAXBicara Therapeutics Inc.	Sell $524.5K · 18,750 sh	2026-08-10	—
BCAXBicara Therapeutics Inc.	Exercise $71.1K · 18,750 sh	2026-08-10	—
BCAXBicara Therapeutics Inc.	Sell $15.5K · 536 sh	2026-07-09	—
BCAXBicara Therapeutics Inc.	Sell $32.6K · 1,075 sh	2026-07-08	—
BCAXBicara Therapeutics Inc.	Sell $128.3K · 4,306 sh	2026-07-08	—
BCAXBicara Therapeutics Inc.	Sell $656.7K · 22,833 sh	2026-07-08	—
BCAXBicara Therapeutics Inc.	Exercise $71.1K · 18,750 sh	2026-07-08	—

BCAXSell

2026-09-08 · Bicara Therapeutics Inc.

$80.7K

—

BCAXSell

2026-09-08 · Bicara Therapeutics Inc.

$320.1K

—

BCAXExercise

2026-09-08 · Bicara Therapeutics Inc.

$66.3K

—

BCAXSell

2026-08-10 · Bicara Therapeutics Inc.

$524.5K

—

BCAXExercise

2026-08-10 · Bicara Therapeutics Inc.

$71.1K

—

BCAXSell

2026-07-09 · Bicara Therapeutics Inc.

$15.5K

—

BCAXSell

2026-07-08 · Bicara Therapeutics Inc.

$32.6K

—

BCAXSell

2026-07-08 · Bicara Therapeutics Inc.

$128.3K

—

BCAXSell

2026-07-08 · Bicara Therapeutics Inc.

$656.7K

—

BCAXExercise

2026-07-08 · Bicara Therapeutics Inc.

$71.1K

—

Newest 10 of 34 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.